Overview

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

The primary purposes of this study are to find out if using high doses of the drug Gefitinib (Iressa) as a way to treat patients with non-small cell lung cancer that has spread to the covering of the brain and/or spinal cord (meninges) results in any bad side effects; and to determine the highest dose that can be given to patients in this setting.

Phase:

Phase 1

Details

Lead Sponsor:

David M. Jackman, MD

Collaborators:

AstraZeneca
Massachusetts General Hospital

Treatments:

Gefitinib